SPDR S&P Biotech ETF $XBI Shares Sold by Osborne Partners Capital Management LLC

Osborne Partners Capital Management LLC cut its stake in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 3.5% during the 4th quarter, HoldingsChannel reports. The fund owned 180,964 shares of the exchange traded fund’s stock after selling 6,601 shares during the period. SPDR S&P Biotech ETF comprises 1.1% of Osborne Partners Capital Management LLC’s portfolio, making the stock its 21st largest position. Osborne Partners Capital Management LLC’s holdings in SPDR S&P Biotech ETF were worth $22,065,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in SPDR S&P Biotech ETF by 27.3% during the third quarter. JPMorgan Chase & Co. now owns 13,538,738 shares of the exchange traded fund’s stock valued at $1,356,582,000 after purchasing an additional 2,900,633 shares during the last quarter. Bessemer Group Inc. increased its stake in SPDR S&P Biotech ETF by 9.3% during the third quarter. Bessemer Group Inc. now owns 1,632,988 shares of the exchange traded fund’s stock valued at $163,624,000 after purchasing an additional 138,322 shares during the last quarter. Ameriprise Financial Inc. increased its stake in SPDR S&P Biotech ETF by 40.5% during the third quarter. Ameriprise Financial Inc. now owns 1,226,147 shares of the exchange traded fund’s stock valued at $122,906,000 after purchasing an additional 353,351 shares during the last quarter. Meitav Investment House Ltd. increased its stake in SPDR S&P Biotech ETF by 70.3% during the third quarter. Meitav Investment House Ltd. now owns 682,056 shares of the exchange traded fund’s stock valued at $68,156,000 after purchasing an additional 281,602 shares during the last quarter. Finally, Greenhouse Funds LLLP increased its stake in SPDR S&P Biotech ETF by 16.6% during the third quarter. Greenhouse Funds LLLP now owns 675,975 shares of the exchange traded fund’s stock valued at $67,733,000 after purchasing an additional 96,308 shares during the last quarter.

SPDR S&P Biotech ETF Price Performance

XBI stock opened at $137.79 on Tuesday. SPDR S&P Biotech ETF has a 1-year low of $74.67 and a 1-year high of $139.19. The firm has a fifty day moving average price of $126.58 and a two-hundred day moving average price of $121.26. The firm has a market cap of $9.09 billion, a price-to-earnings ratio of 11.47 and a beta of 0.88.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.